Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.

Matthew W McCarthySusanna NaggieDavid R BoulwareChristopher J LindsellThomas G StewartG Michael FelkerDushyantha JayaweeraMark SulkowskiNina GentileCarolyn T BramanteUpinder SinghRowena J DolorJuan Ruiz-UngerSybil WilsonAllison DeLongApril RemalyRhonda WilderSean CollinsSarah E DunsmoreStacey J AdamFlorence ThicklinGeorge HannaAdit A GindeMario CastroKathleen McTigueElizabeth ShenkmanAdrian F Hernandeznull null

Published in: medRxiv : the preprint server for health sciences (2022)

Treatment with fluvoxamine 50 mg twice daily for 10 days did not improve time to recovery, compared with placebo, among outpatients with mild to moderate COVID-19. These findings do not support the use of fluvoxamine at this dose and duration in patients with mild to moderate COVID-19.

Keyphrases

double blind
coronavirus disease
placebo controlled
sars cov
clinical trial
phase iii
phase ii
open label
physical activity
randomized controlled trial
squamous cell carcinoma
high throughput
radiation therapy
combination therapy